Vortioxetine-duloxetine

From Psychiatrienet
Revision as of 16:52, 3 March 2015 by Roland (talk | contribs)
Jump to: navigation, search
Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine
Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine

Switch medication from vortioxetine to duloxetine.[1] [2]

Nietinrijdenbord.png Stop vortioxetine
  • Day 1: reduce dosage of vortioxetine to 5 mg/day.
  • Day 7: stop administration of vortioxetine.
Eenrichtingbord.png Start duloxetine
  • Day 8: start administration of duloxetine in a normal dosage of 30-60 mg/day.
  • Day 15: increase the dosage of duloxetine if needed.
Infobord.png More information

[3]

  • Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
  • Duloxetine is a inhibitor of CYP2D6, which metabolizes vortioxetine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. European Medicines Agency | SmPC Brintellix 5 mg.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.